http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-066744-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc |
| filingDate | 2008-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10ea17815e7ae40c82b4c4fa239ad7c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b617d187dab3b5635b1da8a49775cadd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17f2369db68bd934d52764b38f364808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eca8b9e95ad65a6ebde7625d01c6e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9365777c1381ad1afc782fe1e3ff431 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81e2e77d761de0d62c8f0a501510d7a5 |
| publicationDate | 2009-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-066744-A1 |
| titleOfInvention | ACTIVATING COMPOSITIONS OF LIPOPROTEINS LIPASA AND BENZENE COMPOUNDS. TREATMENT METHOD |
| abstract | Use in therapeutic and preventive agents for hyperlipidemia, anti-obesity agents and the like. Claim 1: A method for activating LPL in a patient in need of an LPT activation treatment, which consists in administering an effective amount of a benzene compound to the patient, the benzene compound is represented by the General Formula (1) in which R1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, or phenyl lower alkyl; and R2 is hydrogen; lower alkyl; 1,2,3,4-tetrahydronaphthyl; cycloalkyl lower alkyl; phenyl; phenyl having one or two substituents selected from the group comprising halogen, lower alkoxy, cyano, halogenated lower alkyl and halogenated lower alkoxy; phenyl lower alkyl; phenyl lower alkyl having in the benzene ring one or two substituents selected from the group comprising halogen, lower alkyl, halogenated lower alkyl, cyano, nitro, lower alkoxycarbonyl, carboxy, lower alkoxy, and halogenated lower alkoxy; or lower alkyl having a cycloalkyl and a halogenated phenyl or phenyl; or R1 and R2 join to form -CH = C (Ph) -, where Ph represents phenyl; R3 is hydrogen or lower alkoxy; and Z is a group selected from items (a) to (h) that follow: (a) imidazo [2,1-b] thiazol-6-yl or imidazo [2,1-b] thiazol-6- yl having a lower alkyl substituent; (b) benzimidazol-2-yl; (c) benzothiazol-2-yl; (d) imidazo [1,2-a] pyrimidin-2-yl; (e) imidazol-4-yl having a phenyl or phenyl substituted by halogenated lower alkyl; (f) imidazo [1,2-a] pyridin-3-yl; (g) imidazo [1,2-a] pyridin-5-yl; and (h) a group represented by the following formula: (2) in which R4 is hydrogen, lower alkyl or halogen; R5 is hydrogen, lower alkyl, halogen, hydroxy, lower alkoxy, phenyl lower alkoxy; R6 is hydrogen, lower alkyl, carboxy or halogenated lower alkyl; R7 is hydrogen, lower alkyl, halogen, halogenated lower alkyl, lower alkoxycarbonyl, carboxy, cyano, carbamoyl or phenyl; and R8 is hydrogen or lower alkyl, and it is provided, however, that when Z is a group (e), R1 is lower alkoxy, R2 is phenyl lower alkyl and R3 is hydrogen. |
| priorityDate | 2008-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.